Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis (Q43171700)

15 November 2017

Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis (English)

1 reference

15 November 2017

1 reference

6

Henk-Jan Guchelaar

1 reference

15 November 2017

Wouter M Kooloos

1

1 reference

15 November 2017

Judith Am Wessels

2

1 reference

15 November 2017

Tahar van der Straaten

3

1 reference

15 November 2017

Cornelia F Allaart

4

1 reference

15 November 2017

Tom Wj Huizinga

5

1 reference

15 November 2017

1 February 2010

1 reference

15 November 2017

1 reference

15 November 2017

11

1 reference

15 November 2017

163-175

1 reference

15 November 2017

2

1 reference

Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide

15 November 2017

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Therapeutic strategies in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Pharmacogenomics and individualized drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

The pharmacogenetics of methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Genetic markers of treatment response in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Problems of reporting genetic associations with complex outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Assessing the function of genetic variants in candidate gene association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Characterization of the inosine triphosphatase (ITPA) gene: haplotype structure, haplotype-phenotype correlation and promoter function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Polymorphism at position +896 of the toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Association of polymorphism in the transforming growth factor {beta}1 gene with disease outcome and mortality in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

dbSNP: the NCBI database of genetic variation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

A "silent" polymorphism in the MDR1 gene changes substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

HLA-G and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

The 14 bp deletion-insertion polymorphism in the 3' UT region of the HLA-G gene influences HLA-G mRNA stability

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Polymorphisms of toll-like receptor 2 and 4 genes in rheumatoid arthritis and systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Analysis of transforming growth factor beta1 gene polymorphisms in patients with systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

What makes a good genetic association study?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.139

21 January 2018

Identifiers

DOI

10.2217/PGS.09.139

1 reference

15 November 2017

1 reference